Skip to main content
Shahky Early Access Program Now Available—Sign-up to Learn More
Shahky Early Access Program Now Available—Sign-up to Learn More

For Pharma

The industry’s first exosome-based diagnostics are designed to overcome the limitations of currently available molecular diagnostics and deliver on the true promise of personalized healthcare. We are leaders in collaborating with the biopharmaceutical industry, helping companies leverage exosome-based science to enhance the R&D process, from biomarker discovery through validation, and the development of sophisticated companion diagnostics to maximize the potential of targeted therapies.

Biomarker strategies are incorporated into virtually every R&D process, starting with the earliest stages of clinical development. Sourcing tissue to identify biomarkers can lead to delays in clinical trial recruitment and complicate clinical study design and implementation. By providing biopharma companies with biofluid-based solutions for clinical trials, we can overcome these tissue-related obstacles.

Utilizing our best-in-class technology, we can assess biomarker status without using historical tissue or requiring a biopsy. This offers biopharma companies several key advantages including:

  • Access to a virtually unlimited supply of molecular information via biofluids
  • Enhanced freedom with clinical trial design
  • Accelerated clinical trial enrollment
  • Shortened study duration
  • Reduced overall clinical study costs
  • Potential increased time on patent life

Now available: EXO1000 Liquid Biopsy Mutation Detection Panel

For more information, please contact